TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37004875

Group type: EXPERIMENTAL
Intervention: 3 days of adaptation to threonine intake
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 7 days of adaptation to threonine intake
Number of subjects: 11

Group type: COMPARATOR
Intervention: 1 day of adaptation to threonine intake
Number of subjects: 11
Study: 37004887

Group type: EXPERIMENTAL
Intervention: Methotrexate (combination therapy)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo (monotherapy)
Number of subjects: 297
Study: 37004944

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 273

Group type: COMPARATOR
Intervention: Females
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: AMI-related CS
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Non-AMI-related CS
Number of subjects: 273
Study: 37005448

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 239
Study: 37005486

Group type: EXPERIMENTAL
Intervention: BC-Predict intervention with risk feedback letters
Number of subjects: 2472

Group type: COMPARATOR
Intervention: Usual screening (control)
Number of subjects: 2472
Study: 37005580

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.3 mg/kg bolus over 10 min, followed by 0.3 mg/kg/h infusion)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 mcg/kg bolus over 10 min, followed by 0.5 mg/kg/h infusion)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 90
Study: 37005596

Group type: EXPERIMENTAL
Intervention: Backward walking exercise using lower body positive pressure treadmill
Number of subjects: 26

Group type: COMPARATOR
Intervention: Forward walking exercise using lower body positive pressure treadmill
Number of subjects: 26
Study: 37005636

Group type: EXPERIMENTAL
Intervention: Strict rate control
Number of subjects: 350

Group type: COMPARATOR
Intervention: Lenient rate control
Number of subjects: 350
Study: 37005647

Group type: EXPERIMENTAL
Intervention: rTMS-active stimulus (10 Hz rTMS over individualized-targeted selection area)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rTMS-active stimulus (10 Hz rTMS)
Number of subjects: 30
Study: 37005655

Group type: EXPERIMENTAL
Intervention: Mid-luteal phase target quit date
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Mid-follicular phase target quit date
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual practice (15-30 days after enrollment)
Number of subjects: 1200
Study: 37005891

Group type: EXPERIMENTAL
Intervention: Viltolarsen
Number of subjects: 16

Group type: COMPARATOR
Intervention: CINRG DNHS (historical control)
Number of subjects: 16
Study: 37005961

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 129
Study: 37005959

Group type: EXPERIMENTAL
Intervention: CONUT score
Number of subjects: 371

Group type: COMPARATOR
Intervention: None (mild malnutrition risk group)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Moderate and severe malnutrition risk group
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Other nutritional indices (GNRI, PNI)
Number of subjects: 371
Study: 37005963

Group type: EXPERIMENTAL
Intervention: Forehead (FH) sweat analyte concentrations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Right scapula (RS) sweat analyte concentrations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cortisol concentration over time
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EGF concentration over time
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IL-1ra concentration over time
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IL-6 concentration over time
Number of subjects: 8
Study: 37005966

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 37006132

Group type: EXPERIMENTAL
Intervention: Periodontitis group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gingivitis group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: GCF PLAP-1, sclerostin and TNF-α levels
Number of subjects: 71
Study: 37006227

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 184

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 184
Study: 37006503

Group type: EXPERIMENTAL
Intervention: Minimally invasive trans-sulcal parafascicular surgery (MIPS) approach for ICH removal using the BrainPath
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care involving intensive supportive therapy
Number of subjects: 0
Study: 37006506

Group type: EXPERIMENTAL
Intervention: Early intraprocedural angioplasty and/or stenting (EAS)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Non-angioplasty and/or stenting (NAS)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Late intraprocedural angioplasty and/or stenting (LAS)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: EAS, NAS, LAS
Number of subjects: 475
Study: 37007063

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SABRT) at a starting dose of 40 Gy in 5 fractions
Number of subjects: 10
Study: 37007572

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic normoglycemic clamp (HNC) during surgery (insulin 2 mU/kg/min followed by 20% dextrose infusion to maintain blood glucose between 4.0 and 6.0 mmol/L until end of surgery)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard metabolic care (control group)
Number of subjects: 66
Study: 37007675

Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) models
Number of subjects: 1

Group type: COMPARATOR
Intervention: Multilinear model
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Small datasets recorded later in the experiment
Number of subjects: 1
Study: 37007686

Group type: EXPERIMENTAL
Intervention: Pandemic-related household job losses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pandemic-related economic hardship
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pandemic-related economic hardship and psychosocial distress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pandemic-related psychosocial distress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prepandemic social resources
Number of subjects: 0
Study: 37007736

Group type: EXPERIMENTAL
Intervention: Perineal nerve block
Number of subjects: 192
Study: 37007741

Group type: EXPERIMENTAL
Intervention: Phenotype-tailored lifestyle intervention (PLI) with various approaches based on phenotype: time-restricted volumetric low-calorie diet, low-calorie diet with pre-meal protein supplementation, low-calorie diet with intensive behavioral therapy, low-calorie diet with post-workout protein supplementation and high-intensity interval training.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard lifestyle intervention (SLI) with low-calorie diet, moderate physical activity, and weekly behavioral therapy sessions.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Comparison of PLI vs SLI
Number of subjects: 165
Study: 37007743

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Tα1) therapy
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 37007788

Group type: EXPERIMENTAL
Intervention: FNC (AZVUDINE) added to standard treatment
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo added to standard treatment
Number of subjects: 281
Study: 37007930

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks or 2 mg every 8 weeks after 5 initial monthly doses
Number of subjects: 710

Group type: COMPARATOR
Intervention: Macular laser treatment (control)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 710
Study: 37008165

Group type: EXPERIMENTAL
Intervention: CTPS1 small molecule inhibitor
Number of subjects: 0
Study: 37008185

Group type: EXPERIMENTAL
Intervention: Antenatal group healthy relationship education (MotherWise)
Number of subjects: 507

Group type: COMPARATOR
Intervention: No additional services (Control)
Number of subjects: 507
Study: 37008718

Group type: EXPERIMENTAL
Intervention: Whole blood tacrolimus trough concentration
Number of subjects: 689
Study: 37008796

Group type: EXPERIMENTAL
Intervention: Statistical monitoring using interactive web application (R-Shiny)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Statistical monitoring
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Interactive statistical monitoring
Number of subjects: 422
Study: 37008880

Group type: EXPERIMENTAL
Intervention: RCMP cadets
Number of subjects: 0
Study: 37008891

Group type: EXPERIMENTAL
Intervention: Chin cup and bonded maxillary bite block treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37008942

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and gonadotropin-releasing hormone analogue (GnRHa) for four years
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 16
Study: 37009114

Group type: EXPERIMENTAL
Intervention: Varenicline titrated to 1 mg bid, brief behavioral counseling, and TIQ texting support
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo, brief behavioral counseling, and TIQ texting support
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced usual care (advice to quit and TIQ)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Varenicline titrated to 1 mg bid
Number of subjects: 300
Study: 37009236

Group type: EXPERIMENTAL
Intervention: New legislation banning tobacco sales in supermarkets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobacco industry strategies
Number of subjects: 0
Study: 37009425

Group type: EXPERIMENTAL
Intervention: Guajava leaf treatment, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various treatments for COVID-19, including antiviral agents
Number of subjects: 0
Study: 37009678

Group type: EXPERIMENTAL
Intervention: ETBR-mediated dilation in women with T1D
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Skeletal muscle oxidative capacity in women with T1D
Number of subjects: 19

Group type: COMPARATOR
Intervention: ETBR-mediated dilation
Number of subjects: 19
Study: 37009731

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy
Number of subjects: 104
Study: 37009915

Group type: EXPERIMENTAL
Intervention: At-home serological tests detecting antibodies against SARS-CoV-2 (nucleocapsid or spike antigen), conducted from 1 May 2021 to 31 October 2021.
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Unvaccinated children aged 12-17 years.
Number of subjects: 1058
Study: 37009976

Group type: EXPERIMENTAL
Intervention: Lecanemab plus standard of care (SoC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lecanemab plus SoC
Number of subjects: 0

Group type: COMPARATOR
Intervention: SoC alone
Number of subjects: 0
Study: 37010012

Group type: EXPERIMENTAL
Intervention: ARRY-371797
Number of subjects: 8
Study: 37010101

Group type: EXPERIMENTAL
Intervention: Reduced LVEF (LVEF <50%)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Preserved LVEF (LVEF ≥50%)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Neurohormonal antagonist therapy
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Combined adverse events
Number of subjects: 348
Study: 37010145

Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 810
Study: 37010196

Group type: COMPARATOR
Intervention: Chest physiotherapy (conventional techniques)
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Instrumental techniques
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Forced passive expiratory techniques
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Slow expiratory techniques
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Forced expiratory techniques
Number of subjects: 1679
Study: 37010251

Group type: EXPERIMENTAL
Intervention: LY01005
Number of subjects: 290

Group type: COMPARATOR
Intervention: Goserelin implant
Number of subjects: 290
Study: 37010267

Group type: EXPERIMENTAL
Intervention: Web-based eye test for self-assessing visual function
Number of subjects: 22
Study: 37010495

Group type: EXPERIMENTAL
Intervention: Anti-SAE positive DM
Number of subjects: 49
Study: 37010549

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg qd + Sorafenib 200 mg bid 5 days-on/2 days-off
Number of subjects: 43

Group type: COMPARATOR
Intervention: Everolimus 5 mg qd + Sorafenib (standard schedule)
Number of subjects: 43
Study: 37010829

Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 273

Group type: COMPARATOR
Intervention: Procedural Sedation
Number of subjects: 273
Study: 37010871

Group type: EXPERIMENTAL
Intervention: Longer family mealtime duration (50% longer, average 10 minutes longer)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular family mealtime duration (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Longer family mealtime duration
Number of subjects: 50
Study: 37010888

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program with digital support, 9 sessions
Number of subjects: 5
Study: 37010901

Group type: EXPERIMENTAL
Intervention: Anti-VEGF medications (intravitreal bevacizumab, aflibercept, ranibizumab)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Anti-VEGF medications
Number of subjects: 353
Study: 37010911

Group type: EXPERIMENTAL
Intervention: Warna-Warni Waktu (intervention group, n=924)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Waitlist control condition (control group, n=923)
Number of subjects: 2000
Study: 37010918

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dichoptic action video gaming
Number of subjects: 10
Study: 37010923

Group type: EXPERIMENTAL
Intervention: Tripartite panel of biologically connected immune and metabolic markers
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Blood and stool samples from infants with suspected sepsis
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Blood and stool samples from control infants
Number of subjects: 1445
Study: 37010988

Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (nal-IRI) administered on days 1 and 15, and veliparib on days 5-12 and 19-25 in 28-day cycles.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not applicable as this is a phase I study without a control group.
Number of subjects: 18
Study: 37011013

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 37011024

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study: 37011138

Group type: EXPERIMENTAL
Intervention: Larsucosterol (DUR-928) at doses of 30, 90, or 150 mg administered via intravenous infusion (1 or 2 infusions, 72 hours apart)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Larsucosterol (30 or 90 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard of care (SOC) including corticosteroids
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Larsucosterol (DUR-928)
Number of subjects: 19
Study: 37011153

Group type: EXPERIMENTAL
Intervention: THRIVE app with phone coaching
Number of subjects: 41

Group type: COMPARATOR
Intervention: Symptom-monitoring app with phone coaching
Number of subjects: 41
Study: 37011163

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community participatory approaches; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary, inclusive research team led by a Black psychologist; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intersectionality lens applied; details on dosage and duration not available.
Number of subjects: 0
Study: 37011169

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention to prevent victimization of trans women and trans femmes; details on dosage and duration not available.
Number of subjects: 0
Study: 37011387

Group type: EXPERIMENTAL
Intervention: Video decision support tool
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 330
Study: 37011435

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation
Number of subjects: 0
Study: 37011526

Group type: EXPERIMENTAL
Intervention: Soticlestat (≤300 mg/day twice daily, weight-adjusted)
Number of subjects: 20
Study: 37011643

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (7.5 million international units subcutaneously three times per week for up to 1 year)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R (six cycles every 3 weeks of intravenous dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b after cross-over
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R after cross-over
Number of subjects: 67
Study: 37011650

Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Belzutifan plus cabozantinib
Number of subjects: 52
Study: 37011709

Group type: EXPERIMENTAL
Intervention: Valaciclovir (1 g tid for 8 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 37012012

Group type: EXPERIMENTAL
Intervention: Soprocare camera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumer camera
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference intraoral examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soprocare camera and Consumer camera
Number of subjects: 0
Study: 37012011

Group type: EXPERIMENTAL
Intervention: Risk calculator for pulmonary progression in sarcoidosis patients
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Clinical features measured during routine clinic visits
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Lung function tests (forced vital capacity, forced expiratory volume in 1 s, diffusing capacity of the lung for carbon monoxide)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Blood biomarkers measured during routine clinic visits
Number of subjects: 557
Study: 37012015

Group type: EXPERIMENTAL
Intervention: Oral atorvastatin (40 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 37012016

Group type: EXPERIMENTAL
Intervention: 1.6 mg/kg ilofotase alfa
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study: 37012023

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Spinal instrumentation
Number of subjects: 72
Study: 37012018

Group type: EXPERIMENTAL
Intervention: AI-based model for data extraction from unstructured EHRs
Number of subjects: 100000
Study: 37012068

Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 measurement
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 added to logistic regression model
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 tertiles
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 ≤2.32 pg/mL
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease, creatinine, and estimated glomerular filtration rate
Number of subjects: 476
Study: 37012070

Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 8151

Group type: COMPARATOR
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 8151

Group type: EXPERIMENTAL
Intervention: Causal Forest model
Number of subjects: 8151
Study: 37012180

Group type: EXPERIMENTAL
Intervention: Synchronous chemoradiotherapy (CRT)
Number of subjects: 2297

Group type: EXPERIMENTAL
Intervention: Synchronous CRT
Number of subjects: 2297
Study: 37012181

Group type: EXPERIMENTAL
Intervention: Coronary Intravascular Lithotripsy (IVL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rotational Atherectomy (RA)
Number of subjects: 70
Study: 37012173

Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity measures (METs, number of floors climbed, self-perceived fitness, level of physical activity)
Number of subjects: 15406

Group type: COMPARATOR
Intervention: Clinical risk factors (internal clinical risk model)
Number of subjects: 15406
Study: 37012190

Group type: EXPERIMENTAL
Intervention: Internet-delivered Dialectical Behavior Therapy skills training
Number of subjects: 40
Study: 37012306

Group type: EXPERIMENTAL
Intervention: EGb 761 240 mg orally, 1 tablet daily for 12 months (study group, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n=50) did not receive EGb 761 for the first 12 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EGb 761 240 mg orally, 1 tablet daily for an additional 12 months (after initial 12 months for control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neuropsychological and neurological evaluations at v0, v2, and v4
Number of subjects: 100
Study: 37012318

Group type: EXPERIMENTAL
Intervention: Front-line endocrine therapy for gBRCAm carriers
Number of subjects: 170

Group type: COMPARATOR
Intervention: Front-line chemotherapy
Number of subjects: 170
Study: 37012343

Group type: EXPERIMENTAL
Intervention: Low burden exercise protocol (two six-min walk tests)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 51
Study: 37012461

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets (test formulation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Abiraterone acetate tablets (reference formulation)
Number of subjects: 36
Study: 37012498

Group type: EXPERIMENTAL
Intervention: PSMA guided approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37012549

Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Number of subjects: 32
Study: 37012550

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and cabozantinib
Number of subjects: 0